[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100547581":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":22,"locations":31,"responsibleParty":58,"collaborators":63,"id":98,"slug":10,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":99,"sex":105,"minAge":106,"maxAge":10,"enrollmentInfo":107,"targetDuration":110,"studyType":111,"phases":10,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"University of Florence","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Episodic migraine",null,"Patients affected by an episodic pattern migraine(\\\u003C 15 monthly headache days) with or without aura according to ICHD-III criteria.",[13],"Drug: Rimegepant 75 mg",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Rimegepant 75 mg","Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention",[9],[21],"Rimegepant",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Luigi F Iannone, MD","CONTACT","+393896969606","luigifrancesco.iannone@unimore.it",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":30},"Roberto De Icco, MD","roberto.deicco@mondino.it",[32,47],{"facility":33,"status":34,"city":35,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi","RECRUITING","Florence","50134","Italy",{"type":39,"coordinates":40},"Point",[41,42],11.24626,43.77925,{"lat":42,"lon":41},[45],{"name":24,"role":25,"phone":10,"phoneExt":10,"email":46},"luigifrancesco.iannone@unifi.it",{"facility":48,"status":34,"city":49,"state":49,"zip":50,"country":37,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"IRCCS National Neurological Institute \"C. Mondino\" Foundation","Pavia","27100",{"type":39,"coordinates":52},[53,54],9.15917,45.19205,{"lat":54,"lon":53},[57],{"name":29,"role":25,"phone":10,"phoneExt":10,"email":30},{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":62,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Luigi Francesco Iannone","Researcher","University of Modena and Reggio Emilia",[64,65,67,69,71,73,75,78,80,82,84,86,88,90,92,94,96],{"name":48,"class":6},{"name":66,"class":6},"Società Italiana per lo Studio delle Cefalee",{"name":68,"class":6},"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari",{"name":70,"class":6},"Università degli Studi dell'Aquila",{"name":72,"class":6},"University of Roma La Sapienza",{"name":74,"class":6},"Azienda Ospedaliero Universitaria Policlinico Modena",{"name":76,"class":77},"Ospedale di Piove di Sacco","UNKNOWN",{"name":79,"class":6},"Azienda Ospedaliero-Universitaria di Parma",{"name":81,"class":6},"Azienda Ospedaliera S. Maria della Misericordia",{"name":83,"class":6},"A.O.U. Città della Salute e della Scienza",{"name":85,"class":6},"Cliniche Humanitas Gavazzeni",{"name":87,"class":6},"University of Campania Luigi Vanvitelli",{"name":89,"class":6},"Ospedale Santo Stefano",{"name":91,"class":6},"Azienda Policlinico Umberto I",{"name":93,"class":6},"Auxologico San Luca",{"name":95,"class":6},"Asst Degli Spedali Civili Di Brescia",{"name":97,"class":6},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","100547581",false,"NCT06409832","RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment","RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)","RAISE","Inclusion Criteria:\n\n* Diagnosis of migraine without aura or migraine with aura, according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);\n* At least 4 monthly migraine days;\n* Good compliance to study procedures;\n* Availability of headache diary at least of the preceding months before enrollment.\n\nExclusion Criteria:\n\n* Subjects with contraindications for use of gepants;\n* Diagnosis of chronic migraine\n* Concomitant diagnosis of medical diseases and\u002For comorbidities that, in the Investigator's opinion might interfere with study assessments;\n* medical comorbidities that could interfere with study results;\n* Pregnancy and breastfeeding.\n* Changes in preventive treatments in the month before the first administration of rimegepant","ALL","18 Years",{"count":108,"type":109},100,"ESTIMATED","2 Years","OBSERVATIONAL","The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.",[114,115,116],"Migraine","Migraine With Aura","Migraine Without Aura",[118,119,120,121,122,21],"Headache","Medication overuse headache","Pain","Migraine prevention","Gepant","2026-06-09",{"date":125,"type":126},"2026-06-11","ACTUAL",{"date":128,"type":126},"2024-03-26",{"date":130,"type":109},"2027-09",{"name":5,"class":6},2]